Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

October 23, 2020

Primary Completion Date

October 18, 2024

Study Completion Date

June 30, 2038

Conditions
Gastric AdenocarcinomaPancreatic CancerGastroesophageal Junction Adenocarcinoma
Interventions
DRUG

CT041 autologous CAR T-cell injection

Up to 3 times CT041 autologous CAR T-cell injection infusion

DRUG

Physician's Choice(Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody)

Physician's choice of any BSC listed above

Trial Locations (24)

100142

Beijing Cancer Hospital, Beijing

200025

Ruijin Hospital, affiliated to Shanghai Jiaotong University, school of medicine, Shanghai

200032

Fudan University Shanghai Cancer Center, Shanghai

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

Unknown

Anhui Provincial Cancer Hospital, Hefei

Fujian Medical University Union Hospital, Fuzhou

Peking University Shenzhen Hospital, Shenzhen

Harbin medical university Affiliated Cancer Hospital, Harbin

Henan Tumor Hospital, Zhengzhou

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan

Nanjing Drum Tower Hospital, Nanjing

The Second Affiliated Hospital of Soochow University, Suzhou

Northern Jiangsu People's Hospital, Yangzhou

The Second Affiliated Hospital of Nanchang University, Nanchang

The First Hospital of Jilin University, Changchun

The First Hospital of China Medical University, Shenyang

Shandong Cancer Hospital, Jinan

The Affiliated Hospital of Qingdao University, Qingdao

Shanghai Zhongshan Hospital, Shanghai

Sichuan Cancer Hospital, Chengdu

West China Hospital, Sichuan University, Chengdu

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hanzhou

Sponsors
All Listed Sponsors
collaborator

Peking University Cancer Hospital & Institute

OTHER

collaborator

Fudan University

OTHER

lead

CARsgen Therapeutics Co., Ltd.

INDUSTRY